Search

Additional file 1. Fig.S1: Observed accelerograms and Fourier amplitude spectra at KiK-net KMMH16 and Hi-net N.MSIH stations. a Comparisons of the observed three-component acceleration records, b Fourier amplitude spectra at KiK-net borehole station KMMH16 (black traces) and Hi-net station N.MSIH (red traces) for event EQ18. Note that the original velocity seismograms observed at N.MSIH have been differentiated after the removal of instrumental responses. Fig. S2: Four-day long power spectral density of the recorded seismic noise at site S6. Here the power is expressed as decibel (dB), which corresponds to 10log10(m2/s4/Hz) of spectral acceleration.

76歳男, 健康診断のため施行された腹部CTで左腎腫瘍が疑われ根治的左腎摘出術が施行された。摘除腎の髄質に割面黄褐色で直径約2cmの腫瘍を認め病理組織学的に円柱状で好酸性胞体を有する悪性細胞が乳頭状に増殖していた。レクチンおよび2種のモノクローナル抗体を用いた検討では, Soybean agglutinin, Peanut agglutinin, Dolichos biflorus agglutinin, Lotus tetragonolobus agglutininおよびCytokeratinは弱陽性でTamm-Horsfall proteinが陰性であった。腫瘍の肉眼的および組織学的所見は, 本腫瘍がベリニ管上皮由来であることを強く示唆した。患者は手術後1年を経たが腫瘍の再発を認めず健在である, A case of Bellini duct carcinoma is reported. A left renal tumor was detected by abdominal computerized tomography in a 76-year-old male, although he had no symptoms, such as hematuria, weight loss or flank pain. Radical nephrectomy was performed under the diagnosis of renal cell carcinoma in the left kidney. Macroscopic examination of the resected kidney revealed a tumor 2.0 cm in diameter, with a yellow-brown cut surface, located in the renal medulla. Histological examinations showed malignant tumor cells with eosinophilic cytoplasm with a papillary growth pattern. Immunohistostaining examinations using Lectin and two kinds of monoclonal antibodies demonstrated no significant staining with soybean agglutinin, peanut agglutinin, Dolichos biflorus agglutinin, Lotus tetragonolobus agglutinin or cytokeratin, and negative staining with Tamm-Horsfall protein. Although the results of immunohistostaining did not provide support, both macroscopic and microscopic findings strongly suggested that this tumor originated from Bellini duct epithelium (Bellini duct carcinoma). The patient is alive with no evidence of disease 1 year after surgery. Bellini duct carcinoma is a rare malignant condition and the prognosis is usually poor. Differential diagnosis from other renal or pelvic tumors is difficult and long-term careful follow-up is necessary.

術後3ヵ月以上経過した31例を検討対象とした。生存期間中央値は32ヵ月(3-95ヵ月)で, 5例が死亡した。その死因は2例が前立腺癌, 1例が心筋梗塞, 1例が肺炎, 1例が術後死であった。再発は4例に認められた。stage Bの1例は術後22ヵ月目に骨転移が生じたが, 去勢術と前術したmethotrexate投与にてPR状態で32ヵ月, pN1の1例は術後53ヵ月目に尿道膀胱吻合部に再発し, Honvanの経口投与と局所放射線療法によりCR状態で95ヵ月いずれも生存中である。残りの2例はpN2症例で, 1例は術後34ヵ月目に尿道膀胱吻合部と骨に, 1例は4ヵ月目に頸部リンパ節に再発し, 前者は65ヵ月, 後者は23ヵ月後に癌死した, Total retropubic prostatectomy was performed on 31 patients with prostatic cancer (median age; 70 years). The accuracy of staging was 55% (17 patients). In 11 patients (35%) the staging had been underestimated, and in 3 patients (10%) overestimated. The pathological stage and grade were stage B in 14 patients, stage C in 4 patients, stage D1 in 13 patients (pN1; 8 patients, pN2; 5 patients), well differentiated adenocarcinoma (WDA) in 8 patients moderately differentiated adenocarcinoma (MDA) in 7 patients, and poorly differentiated adenocarcinoma (PDA) in 16 patients. The WDA were all stage B, and 85% of the PDA were stage D1. The positive surgical margin rate was 21% in stage B, 50% in stage C, 85% in stage D1, 13% in WDA, 43% in MDA, and 75% in PDA. Five of the patients died, and the causes of death were prostatic cancer in 2 patients (pN2/PDA), and others in 3 patients (1 patient; stage B/PDA, 2 patients; pN2/PDA). The 5-year survival rate (Kaplan-Meier) was 84% on the whole, 83% for stage B, 100% for stage C, 83% for stage D1, 100% for WDA, 100% for MDA, 71% for PDA, 86% for pN0, 100% for pN1, and 38% for pN2.

49歳男, 腎細胞癌による根治的腎摘出術後12年目に摘出後遺残尿管と膀胱に移行上皮癌の発生した例, A 49-year-old male with left renal cell carcinoma and urothelial cancer (bladder and residual left ureter), which asynchronously occurred, was reported. He had received radical nephrectomy due to renal cell carcinoma 12 years earlier. He was followed up by his local physician for 7 years postoperatively, during which time no metastatic lesion was detected. However, he presented with macroscopic hematuria on January 7, 1992, and a diagnosis of urinary bladder cancer was made at our hospital. Computerized tomography demonstrated a non-papillary, broad-based tumor on the left wall of the urinary bladder, which histologically was transitional cell carcinoma (grade 3). Radical cystectomy, ureterectomy of the left residual ureter and ileal conduit were performed. Histological examinations showed that the urinary bladder tumor was transitional cell carcinoma, grade 3, pT-3b, and CIS (transitional cell carcinoma, grade 3) was found in the residual left ureter. Chemotherapy containing cis-platinum was performed as an adjuvant therapy, but multiple lung metastatic lesions appeared 2 months postoperatively, the histology of which was transitional cell carcinoma, suggesting metastasis from the urothelial cancer. Chemotherapy was ineffective, and he died of the disease 9 months after the operation. If this patient had been under long-term follow-up, the urothelial cancer may have been resected completely by transurethral resection. Our report indicated the importance of examination of the urinary tract in patients with such cancers, as well as the necessity of long-term follow-up.

血清basicfetoproteinが高値を呈した傍精巣平滑筋腫の1例を報告する.患者は45歳男性で6ヵ月前より左陰嚢内容の無痛性腫大を自覚し当科を受診した.左精巣腫瘍の診断の下に左高位除聖術が施行された.肉眼的および病理組織学的所見より摘除腫瘍は傍精巣平滑筋肉腫であった.血清basicfetoproteinは新しく同定された胎児性蛋白で, ある種の悪性腫瘍で高値を示す.自験例では術前血清basicfetoprotelnが高値を示し, その値は患者の病状とよく相関した.化学療法および, 肺転移巣切除にもかかわらず患者の全身状態が悪化するとともに血清baslcfetoprotein値は上昇し, 患者は入院後2年6ヵ月目に癌死した.血清basicfetoproteinは自験例では有用な腫瘍マーカーであると思われた., A case of paratesticular leiomyosarcoma associated with elevated serum basic fetoprotein level is reported. A 45-year-old male visited our hospital with a 6-month history of a painless left scrotal mass. High orchiectomy was performed under the diagnosis of left testicular tumor. Macroscopic and microscopic examination of the resected tumor demonstrated it to be paratesticular leiomyosarcoma. The value of serum basic fetoprotein, which is a newly identified oncofetal protein and useful as a tumor marker in some kinds of malignant neoplasm, was elevated before therapy, and its fluctuation was correlated with his clinical course. In spite of chemotherapy and resection of metastatic lesions in the lung, his condition gradually deteriorate with increasing serum basic fetoprotein level, and he died with carcinomatosis 2 years and 6 months after his admission. We suggest that basic fetoprotein is a useful tumor marker in this disease.

DELFIA PSAの臨床的検討を2施設の共同研究で行った.本法はeuropiumをtracerとしたtime-resolved fluoroimmunoassayであり, 0.10～500 ng/mlという3.5 logにおよぶ広い測定範囲を有しており, 検体必要量も25 μlと少量で済み, 再現性にも優れ, さらに自動化も可能であった.また, 本法はTander-R PSAと同一のPSA値となることも特色である.健常男性227例の血清PSA値の平均+3S.D.から, 1.98 ng/mlを正常上限値と決定した.一方, 前立腺癌とBPHを鑑別するもっとも効率的なcutt-off値として, BPH症例の平均+S.D.値である11.7 ng/mlが優れていた.さらに, 前立腺癌症例のフォローアップにおける有用性はきわめて高いことが確認できた, Serum prostate specific antigen (PSA) values detected by DELFIA PSA were evaluated for usefulness in the diagnosis and follow-up of patients with prostate cancer. The system is time-resolved fluoroimmunoassay using europium as a tracer, which has a detectable range of 0.10-500 ng/ml with a small sample volume (25 microliters) and reliable quality control data. Furthermore, serum PSA values detected by the assay were equivocal to those detected by Tandem-R PSA. From the mean +3 S.D. of serum PSA values obtained on 227 normal males, 1.98 ng/ml was decided as an upper normal level. Serum PSA values in benign prostatic hyperplasia (BPH) (n = 69) and prostate cancer (n = 86) patients were statistically higher than those in normal males. However, when 1.98 ng/ml was used as a cut-off value, the false positive rate in BPH cases elevated up to 80%. Therefore, in the differential diagnosis of prostate cancer and BPH, we recommend 11.7 ng/ml (mean + S.D. in BPH cases) as a cut-off value, in which sensitivity is 72.1%, 88.4% are true negative in BPH, and efficacy is 79.4%. Serially determined serum PSA values in following up the patients with prostate cancer were confirmed to be highly effective for diagnosing recurrence and evaluating treatment responses. These findings suggest that DELFIA PSA is a useful tool for determination of serum PSA values.

Total retropubic prostatectomy was performed on 31 patients with prostatic cancer (median age; 70 years). The accuracy of staging was 55% (17 patients). In 11 patients (35%) the staging had been underestimated, and in 3 patients (10%) overestimated. The pathological stage and grade were stage B in 14 patients, stage C in 4 patients, stage D1 in 13 patients (pN1; 8 patients, pN2; 5 patients), well differentiated adenocarcinoma (WDA) in 8 patients moderately differentiated adenocarcinoma (MDA) in 7 patients, and poorly differentiated adenocarcinoma (PDA) in 16 patients. The WDA were all stage B, and 85% of the PDA were stage D1. The positive surgical margin rate was 21% in stage B, 50% in stage C, 85% in stage D1, 13% in WDA, 43% in MDA, and 75% in PDA. Five of the patients died, and the causes of death were prostatic cancer in 2 patients (pN2/PDA), and others in 3 patients (1 patient; stage B/PDA, 2 patients; pN2/PDA). The 5-year survival rate (Kaplan-Meier) was 84% on the whole, 83% for stage B, 100% for stage C, 83% for stage D1, 100% for WDA, 100% for MDA, 71% for PDA, 86% for pN0, 100% for pN1, and 38% for pN2.